Should I Buy INMB? INMB 2026 Analysis

Should You Buy INmune Bio Inc (INMB) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion

Hold

Latest Price

1.590

1 Day change

1.92%

52 Week Range

11.640

Analysis Updated At

2026/01/29

INmune Bio Inc (INMB) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock shows no significant positive catalysts, weak financial performance, and no clear technical or options-based trading signals to suggest immediate upside potential. Holding off on this investment is recommended until stronger indicators emerge.

Technical Analysis

The MACD is slightly positive but contracting, RSI is neutral at 39.687, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 1.533), but there is no strong bullish momentum. The stock has a 70% chance to decline by -1% in the next day and shows minimal upside in the next week or month.

Options Data

Bullish

Open Interest Put-Call Ratio

Bearish

Option Volume Put-Call Ratio

The high put-call volume ratio indicates bearish sentiment among options traders, with significantly higher put volume compared to call volume. This suggests traders are positioning for potential downside.

Technical Summary

Sell

Buy

Positive Catalysts

NULL identified. No recent news or significant insider/hedge fund activity to act as a positive catalyst.

Neutral/Negative Catalysts

Weak financial performance in Q3 2025, with a 46.48% drop in net income and a 60% decline in EPS YoY. Options data suggests bearish sentiment, and technical indicators show no clear upward momentum.

Financial Performance

In Q3 2025, revenue remained at 0 with no growth YoY. Net income dropped significantly by -46.48% YoY to -$6.47M, and EPS fell by -60% YoY to -0.24. Despite a 100% gross margin, the lack of revenue and declining profitability indicate poor financial health.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target changes are available for INMB.

2 Analyst Rating

Wall Street analysts forecast INMB stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for INMB is 8 USD with a low forecast of 8 USD and a high forecast of 8 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

1 Hold

0 Sell

Moderate Buy

Current: 1.560

Low

Averages

High

Current: 1.560

Low

Averages

High

Alliance Global Partners

Buy

downgrade

$20 -> $7

AI Analysis

2025-07-03

Reason

Alliance Global Partners

Price Target

$20 -> $7

AI Analysis

2025-07-03

downgrade

Buy

Reason

Alliance Global Partners lowered the firm's price target on INmune Bio to $7 from $20 and keeps a Buy rating on the shares after the company reported topline Phase 2 data from the MINDful trial of XPro for Alzheimer's disease that "were not what we had hoped for." The firm adjusted its price target to account for the added uncertainly around the future development for XPro and the additional time that will be needed to find a partner and start confirmatory trials, noting that it now values XPro for Alzheimer's at $3 per share.

Maxim

Jason McCarthy

Buy

downgrade

$30 -> $8

2025-07-02

Reason

Maxim

Jason McCarthy

Price Target

$30 -> $8

2025-07-02

downgrade

Buy

Reason

Maxim analyst Jason McCarthy lowered the firm's price target on INmune Bio to $8 from $30 but keeps a Buy rating on the shares. The firm cites the failure of lead drug XPro to demonstrate clinical improvements in the company's Phase 2 Alzheimer's disease trial, but while the top-line data is disappointing, there were some promising aspects and the company continues to develop its pipeline, the analyst tells investors in a research note.

Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for INMB

Unlock Now

INMB Should I Buy

INMB Should I Buy

Should You Buy INmune Bio Inc (INMB) Today? Analysis, Price Targets, and 2026 Outlook.

Technical Analysis

Options Data

Technical Summary

Positive Catalysts

Neutral/Negative Catalysts

Financial Performance

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

People Also Watch